摘要
表观遗传学调控异常在血液系统恶性肿瘤的发生、发展过程中发挥重要作用。Zeste基因增强子同源物(EZH)2,为多梳家族(PcG)重要成员之一,其通过特异性催化组蛋白H3上第27位赖氨酸三甲基化(H3K27me3)调控靶基因转录。多种血液系统恶性肿瘤中,存在EZH2的持续高表达,其与肿瘤的侵袭性及疾病预后不良相关。在不同类型的血液系统恶性肿瘤中,EZH2基因突变对H3K27me3的影响截然不同。笔者拟就EZH2与血液系统恶性肿瘤的关系,以及相关靶向药物的应用,对EZH2在血液系统恶性肿瘤中的研究现状进行阐述。
Epigenetic regulatory abnormalities play an important role in the occurrence and development of hematological malignant neoplasms.Enhancer of Zeste homolog(EZH)2 is one of the important members of the polycomb group(PcG),which regulates the transcription of target genes through the specific catalytic tri-methylation at lysine 27 of histone H3(H3K27me3).EZH2 is consistently highly expressed in a variety of hematological malignant neoplasms,which is associated with neoplasms invasiveness and poor prognosis of patients.The effect of EZH2 gene mutation on H2K27me3 is quite different in different types of hematological malignant neoplasms.This article intends to surmmarize the research status of EZH2 in hematological malignant neoplasms on the relation between EZH2 and hematological malignant neoplasms,as well as the applications of relevant targeted drugs.
作者
张永甜
邱婷婷
徐开林
Zhang Yongtian;Qiu Tingting;Xu Kailin(Department of Hematology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221002,Jiangsu Province,China)
出处
《国际输血及血液学杂志》
CAS
2020年第2期104-108,共5页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金(81400129)
中国博士后科学基金(2015113010)。
